Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22624832.
- Also identified by DOI 10.1016/j.jacc.2011.09.086 and PMC identifier 4230443.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cyclic guanosine monophosphate (cGMP) is an important intracellular second messenger that mediates multiple tissue and cellular responses. The cGMP pathway is a key element in the pathophysiology of the heart and its modulation by drugs such as phosphodiesterase (PDE)-5 inhibitors and guanylate cyclase activators may represent a promising therapeutic approach for acute myocardial infarction, cardiac hypertrophy, heart failure, and doxorubicin cardiotoxicity in patients. In addition, PDE-5 inhibitors may prove to be innovative therapeutic agents for enhancing the chemosensitivity of doxorubicin while providing concurrent cardiac benefit.
Medical subject headings
- Guanosine Monophosphate
- Heart Diseases
- Myocytes, Cardiac
- Phosphodiesterase 5 Inhibitors